HC Wainwright reiterated their buy rating on shares of OKYO Pharma (NASDAQ:OKYO – Free Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $7.00 price objective on the stock. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.
OKYO Pharma Price Performance
NASDAQ OKYO opened at $1.26 on Thursday. OKYO Pharma has a twelve month low of $0.81 and a twelve month high of $2.12. The company’s 50-day simple moving average is $1.05 and its 200 day simple moving average is $1.24.
About OKYO Pharma
Recommended Stories
- Five stocks we like better than OKYO Pharma
- How to Buy Cheap Stocks Step by Step
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What is a Secondary Public Offering? What Investors Need to Know
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Evaluate a Stock Before BuyingÂ
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.